National Institutes of Health

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Mount Sinai Health System is an integrated healthcare system based in New York, providing exceptional medical care to local and global communities. Established in 2013 through the merger of Mount Sinai Medical Center and Continuum Health Partners, it encompasses the Icahn School of Medicine and operates seven hospital campuses throughout the New York metropolitan area. The system is recognized for its excellence in research, patient care, and education across various specialties. It features a vast network of over 7,000 primary and specialty care physicians, as well as more than 45 ambulatory practices and 12 minority-owned free-standing ambulatory surgery centers. Mount Sinai is committed to improving healthcare quality and accessibility, focusing on compassionate patient experiences and the development of strong relationships between staff and patients. Additionally, its venture capital arm, Mount Sinai Ventures, invests in healthcare startups, further enhancing its capacity to innovate and respond to the diverse health needs of the populations it serves.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Weill Cornell Medicine operates as a leading medical and graduate school in New York City, focusing on excellence in patient care, scientific discovery, and the education of future physicians. The institution provides a comprehensive range of services, including medical consultancy, healthcare programs, and educational guidance, aimed at healthcare service providers, medical students, and governmental organizations. In addition to its educational mission, Weill Cornell Medicine includes specialized centers such as the Weill Cornell Vein Treatment Center, which offers treatments for various venous conditions and related health issues. The Information Technologies & Services Department plays a crucial role in supporting the institution’s objectives by delivering extensive IT infrastructure and services, enhancing research and clinical operations through innovative technology solutions. This multidisciplinary approach positions Weill Cornell Medicine as a leader in both medicine and technology.

The New York Society for the Prevention of Cruelty to Children is a charity that offers counseling, legal, and educational services.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing radiotherapies for patients with cancer. The company's lead product candidate, Iomab-B, is undergoing a pivotal Phase III clinical trial as a conditioning agent for patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to bone marrow transplantation. Another key candidate, Actimab-A, is in Phase II trials targeting newly diagnosed acute myeloid leukemia in patients aged 60 and older. Additionally, Actinium is developing Actimab-M for penta-refractory multiple myeloma, currently in Phase I trials. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. Actinium also collaborates with Astellas Pharma to advance its technology. Founded in 2000, Actinium Pharmaceuticals aims to address unmet medical needs in hematology through innovative therapeutic approaches.

Daxor Corporation is a medical device and biotechnology firm based in New York, specializing in blood volume measurement. The company developed the BVA-100 Blood Volume Analyzer, which is the first FDA-approved instrument designed to provide rapid and accurate measurement of a patient's true blood volume. This innovative device is utilized in diagnosing and treating various medical conditions, including congestive heart failure, hypertension, and anemia, among others. Daxor also offers additional services such as semen banking, blood storage, and laboratory testing. The company has established a cooperative research agreement with the Uniformed Services University of the Health Sciences to study the efficacy of the BVA-100 in assessing blood volume in traumatic injury contexts. Founded in 1970 and originally known as Idant Corporation, Daxor Corporation has positioned itself at the forefront of medical instrumentation technology.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and located in Winchester, Massachusetts. The company focuses on developing immune-based therapies for cancer and chronic infectious diseases. A key aspect of its research involves targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and addressing the specific population of TNFR2 regulatory T cells present in the tumor microenvironment. Through its innovative approaches, Boston Immune Technologies aims to advance immunotherapy options for patients facing these challenging health conditions.

Columbia University is a prestigious research institution and an Ivy League school located in New York City. It is renowned for its academic rigor and diverse international faculty and student body. The university actively engages with the city's resources to enhance its research and teaching initiatives, fostering global academic partnerships and advancing knowledge across various disciplines. Columbia is committed to sharing the outcomes of its research worldwide, creating a significant impact in both academia and society. The university's endowment supports numerous initiatives, including scholarships, professorships, fellowships, and research programs, reinforcing its dedication to academic excellence and public service.

MaineHealth is a not-for-profit family of leading high-quality providers and other healthcare organizations working together so our communities are the healthiest in America. Ranked among the nation's top 100 integrated healthcare delivery networks, MaineHealth member organizations include Maine Medical Center, Franklin Community Health Network, LincolnHealth, Maine Behavioral Healthcare,

Barrett Technology, LLC, established in 1990 and located in Newton, Massachusetts, specializes in the design and manufacture of advanced robotic manipulators. The company has developed pioneering technology that enhances the flexibility of articulated arms and hands, positioning itself as a leader in the field. Barrett's innovative manipulators have earned recognition, including a place in the Guinness Book of World Records, for their superior capabilities. The company's products offer exceptional versatility, making them suitable for a wide range of applications across various industries.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery and manufacturing technologies. Founded in 1993, Aphios develops innovative platforms that enhance drug discovery and ensure the safety of pharmaceuticals. The company focuses on creating therapeutic products aimed at health maintenance, disease prevention, and treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-derived therapeutic, and several advanced formulations such as APH-0703, a protein kinase C activator, and APH-0911, a nanotechnology-based prodrug for cancer treatment. Additionally, Aphios is engaged in developing technologies related to supercritical fluids for the production of natural pharmaceuticals, as well as specialized equipment for various applications, including microbial cell disruption and biomass pretreatment for biofuels. The company also provides virology testing services to validate viral clearance and inactivation.

Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

The Mount Sinai School of Medicine in New York, New York, one of the only schools in the nation with a distinctive Department of Medical Education that continually improves the quality of its teaching, offers students a variety of medical academics to shape them into compassionate assistants, professionals and industry leaders. The academics available at Mount Sinai include master's and PhD programs in areas like: * Science and Medicine * Patient Oriented Research Training and Leadership * Biomedical Sciences * Genetic Counseling * Clinical Research Besides its degree-granting programs, Mount Sinai also offers an extensive number of residencies and fellowships, some of which include: * Anesthesiology * Cardiology * Dental Medicine * Emergency Medicine * Hematology and Oncology College life at Mount Sinai is fully-immersed in the medical sciences. All your instruction, provided by medical professionals, will be delivered in a hospital setting, allowing you to familiarize yourself with the many resources and technology used in today's hospitals. Mount Sinai is also home to the Levy Library, which is fully-stocked with myriad medical resources, from journals to professional magazines to textbooks. Since each program has different admissions requirements, please contact Mount Sinai for more information on a program that interests you and your career goals. Tuition assistance is available to students through fellowship programs and Mount Sinai grants and scholarships. For more information federal sources of financial aid, please contact an aid advisor from the school.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

The University of Pittsburgh, established in 1787 as the Pittsburgh Academy, is a prominent state-related research university recognized for its academic excellence and research capabilities. It is a member of the Association of American Universities, which includes 62 leading doctorate-granting institutions in North America. The university ranks 24th globally and is recognized as one of the top public universities in the United States, holding the top position in Pennsylvania. The University of Pittsburgh is noted for its strong research productivity and impact, as evidenced by its high ranking in the Performance Rankings of Scientific Papers for World Universities. The university's Pittsburgh School of Medicine, founded in 1886, provides professional medical education, including a Doctor of Medicine (MD) degree. Pitt's students have received numerous prestigious awards, including four Rhodes Scholarships between 2006 and 2012, making it one of the few public institutions to achieve such recognition.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Actuated Medical, Inc. engages in outsourced research and development, designing and modeling, prototyping, and manufacturing medical devices. It offers occlusion clearing systems, such as NG-Clear for removing and disintegrating nasogastric (NG) tube clogs; and PEG-Clear for clearing and breaking up percutaneous endoscopic gastrostomy (PEG) tube clogs. The company also provides controlled tissue penetration systems, including resonance assisted insertion lancets for humane blood sampling of research subjects; low insertion force epidural systems for the entry of epidural needles; and resonance assisted vascular entry needles for aiding in vascular access for compromised and difficult access patients. In addition, Actuated Medical, Inc. offers magnetic resonance imaging compatible systems, such as direct drive motor for improving patient care by enabling various diagnostic and surgical procedures to be performed during MRI imaging; and transdermal patches for administering long-term and controlled-delivery medications subcutaneously. The company was formerly known as Piezo Resonance Innovations, Inc. and changed its name to Actuated Medical, Inc. in September 2011. Actuated Medical, Inc. was founded in 2006 and is based in Bellefonte, Pennsylvania.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Albert Einstein College of Medicine is a research-intensive medical school located in the Bronx, New York. Established in 1953, it offers a variety of academic programs, including medical degrees and graduate programs in biomedical sciences, as well as advanced training in clinical and research disciplines. The college is committed to preparing a diverse group of students to become knowledgeable and compassionate physicians alongside innovative scientific investigators. Emphasizing medical research and education, Albert Einstein College of Medicine provides students with opportunities to engage in groundbreaking scientific work and collaborates with hospitals and research institutions to enhance healthcare and improve patient outcomes.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Simulations Plus is a developer of specialized software focused on Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) as well as Physiologically-Based Pharmacokinetic (PBPK) modeling and simulation. Founded in 1996 and headquartered in Lancaster, California, the company serves various sectors, including pharmaceuticals, biotechnology, chemicals, cosmetics, and food ingredients. Its software enables pharmaceutical scientists to predict key endpoints and dynamics in silico, effectively lowering research and development costs while facilitating informed decision-making. Simulations Plus employs over 60 individuals and has a consulting team based in Buffalo, New York. The company’s technology is licensed by 19 of the top 20 pharmaceutical companies, along with a range of mid-sized and smaller firms, as well as major regulatory agencies. Additionally, trusted distributors manage sales and scientific support in Asian markets.

Weill Cornell Medicine operates as a leading medical and graduate school in New York City, focusing on excellence in patient care, scientific discovery, and the education of future physicians. The institution provides a comprehensive range of services, including medical consultancy, healthcare programs, and educational guidance, aimed at healthcare service providers, medical students, and governmental organizations. In addition to its educational mission, Weill Cornell Medicine includes specialized centers such as the Weill Cornell Vein Treatment Center, which offers treatments for various venous conditions and related health issues. The Information Technologies & Services Department plays a crucial role in supporting the institution’s objectives by delivering extensive IT infrastructure and services, enhancing research and clinical operations through innovative technology solutions. This multidisciplinary approach positions Weill Cornell Medicine as a leader in both medicine and technology.

NYU Langone Health is a nonprofit academic medical center located in New York City, renowned for its commitment to patient-centered care, medical education, and research. It offers a comprehensive range of services, diagnosing and treating various conditions including lung diseases, joint and muscle disorders, neurological disorders, blood disorders, and gastrointestinal issues. As a center of excellence, NYU Langone Health integrates clinical care with cutting-edge research and education, ensuring high-quality healthcare for its patients while advancing medical knowledge and practices.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company founded in 2017 that specializes in developing and commercializing a wearable microfluidic sensing platform. This innovative technology analyzes small droplets of sweat directly from the skin to provide insights into health, hydration, and athletic performance. The platform is designed to measure various biomarkers, including proteomics and inflammatory markers, allowing for personalized management of health and nutrition. Epicore's approach leverages over two decades of research in microfluidics and soft materials conducted by leading experts at Northwestern University. By offering a non-invasive and cost-effective solution, Epicore aims to enhance athletic performance and improve overall health monitoring for users.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases. The company has a diverse pipeline that includes gene therapy programs for rare genetic disorders and various chimeric antigen receptor (CAR) T cell therapies targeting both hematologic malignancies and solid tumors. Notable projects include MB-107, a gene therapy aimed at treating X-linked severe combined immunodeficiency, which is currently undergoing Phase 1/2 clinical trials. Other therapies under development include MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and multiple CAR T programs targeting glioblastoma, prostate cancer, and pancreatic cancer. Mustang Bio also collaborates with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center for research and development in gene editing and oncolytic viruses. Established in 2015 and headquartered in New York, Mustang Bio operates as a subsidiary of Fortress Biotech, Inc.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, founded in 2014. It specializes in developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. The company utilizes a synthetic amplifier technology that enhances the speed and complexity of antibiotic susceptibility testing, facilitating quicker and more accurate selection of personalized antimicrobial therapies for patients. By streamlining the identification of effective treatments, SeLux Diagnostics aims to improve patient care, reduce hospital stays, and tackle the growing issue of antibiotic resistance by minimizing the reliance on broad-spectrum antibiotics.

Drexel University is a comprehensive global research institution located in Philadelphia, recognized among the top 100 universities in the United States. With a student population of approximately 26,000, it ranks as one of the country's largest private universities. Drexel is renowned for its leadership in experiential learning, particularly through its co-op program, and is distinguished by its history of technological innovations and translational research practices. The university operates three campuses in Philadelphia and additional regional sites, including Drexel University Sacramento, and is home to the Academy of Natural Sciences, the oldest major natural science museum in the nation. Drexel also has established international research partnerships, notably in China and Israel, and offers a robust online degree program. As one of Philadelphia's top employers, Drexel plays a significant role in the region's economic development and is committed to civic engagement, integrating community partnerships throughout its academic and service endeavors. Additionally, the university manages an endowment fund that supports scholarships, financial aid, and various operations, guided by its board of trustees and investment committee.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

Soligenix, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases and public health solutions. The company operates through two primary segments: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics segment, Soligenix is advancing SGX301, a photodynamic therapy for cutaneous T-cell lymphoma that has completed Phase 3 clinical trials, and SGX942, aimed at treating oral mucositis in head and neck cancer, currently in Phase 3 trials. Additionally, it is developing an oral formulation of beclomethasone dipropionate for severe gastrointestinal disorders in early clinical trials. The Public Health Solutions segment focuses on biodefense, including the development of RiVax, a vaccine candidate against ricin toxin, which has completed early clinical trials, and SGX943, a therapeutic for antibiotic-resistant infections that is in pre-clinical development. The company also works on technologies like ThermoVax, aimed at stabilizing vaccines. Soligenix was founded in 1987 and is based in Princeton, New Jersey.

The University of Vermont (UVM) is a public research university located in Burlington, Vermont, established in 1791. It is one of the oldest institutions of higher education in the United States and the fifth college founded in New England. UVM offers a diverse array of academic programs through its various schools and colleges, including the School of Business Administration, College of Agriculture and Life Sciences, College of Arts and Sciences, College of Communication, College of Medicine, College of Engineering and Mathematics, Graduate College, College of Nursing and Health Sciences, College of Education and Social Services, and School of Natural Resources. The university's campus spans 451 acres and features notable sites such as the historic University Green, the environmentally certified Dudley H. Davis Center, the Fleming Museum of Art, and the Gutterson/Patrick athletic complex. Additionally, the university is affiliated with Fletcher Allen Health Care, the largest hospital complex in Vermont, which is located adjacent to the campus and collaborates with the College of Medicine.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

Akelos, Inc. is a biopharmaceutical company based in New York, focusing on the development of novel non-narcotic drugs aimed at treating neuropathic pain. Founded in 2018, the company is dedicated to addressing the opioid epidemic by creating alternatives to opioid therapies. Currently, Akelos is advancing two drug candidates through pre-clinical development stages. Additionally, the company has initiated a research collaboration to develop and commercialize a unique non-opioid anti-hyperalgesic drug specifically designed for chronic and neuropathic pain management. Akelos strives to tackle significant unmet medical needs in pain management through innovative scientific approaches.

WindGap Medical is a biotech company that manufactures medical devices used to treat patients with severe allergies. The company develops auto-injectors that are filled with heat-stable epinephrine that enable physicians to inject it into a patient suffering from anaphylaxis due to an acute allergy attack. The company was established in 2011 and is headquartered in Somerville, Massachusetts.

Rutgers University, officially known as Rutgers, The State University of New Jersey, is a prominent institution for higher education, established in 1766 as Queen's College, making it the eighth-oldest college in the United States. As the largest university in New Jersey's state university system, Rutgers offers over 100 undergraduate, 100 master's, and 80 doctoral and professional degree programs across 175 academic departments and 29 degree-granting schools and colleges, with 16 offering graduate programs. The university also has a dedicated School of Law that covers various legal fields. Rutgers manages an endowment fund based in New Brunswick, which serves as a vital source of income to support its mission. This endowment funds student aid, innovative teaching programs, pioneering research, and the development of new technologies.

POP Biotechnologies is a life sciences company based in Buffalo, NY, focused on enhancing individual health through innovative nanomedicine solutions. The company develops targeted therapies aimed at treating cancer and other serious diseases, utilizing advanced nanoparticle-based drug delivery systems. Their proprietary technology allows for the precise release of drug payloads when activated by near-infrared light, providing healthcare providers with effective tools to address patient needs in oncology and infectious diseases.

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company specializes in developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its HEALER technology platform, Thetis Pharmaceuticals focuses on the pharmacology of lipids to create new and patented small molecule drugs that promote tissue regeneration and mitigate inflammation. Their research has advanced the development of resolvins, which act as potent agonists of inflammation resolution and tissue repair. These therapies are designed to counteract excessive inflammatory responses while preserving immune function, thereby enabling healthcare professionals to better manage patients' inflammatory conditions.

On July 1, 2013, the New Jersey Medical and Health Sciences Education Restructuring Act went into effect, integrating Rutgers, The State University of New Jersey, with most of the schools of the University of Medicine and Dentistry of New Jersey (UMDNJ), including New Jersey Dental School.

Hackensack Meridian Health is a not-for-profit healthcare organization based in New Jersey that provides a comprehensive range of medical services and life-enhancing care. The organization operates a network that includes ambulatory care centers, surgery centers, home health services, long-term care facilities, and assisted living communities. Additionally, it offers ambulance services, lifesaving air medical transportation, rehabilitation services, urgent care, and fitness and wellness centers. Through its integrated approach, Hackensack Meridian Health aims to deliver innovative research and improve health outcomes for the communities it serves.

Skelmet Inc. is a Boston-based company that specializes in the design and production of custom head-worn products, including sunglasses, lenses, nose and temple pads, and carrying cases tailored for various sports such as running, cycling, skiing, golfing, sailing, and fishing. Founded in 2015, Skelmet utilizes advanced 3D Fit technology, which combines 3D scanning and 3D printing to create bespoke items that ensure a perfect fit for each individual user. The company has introduced products like the Falcon I bespoke sport sunglasses, which are lightweight and engineered for optimal performance and protection. Skelmet's offerings cater to active individuals seeking personalized and high-quality eyewear, and they are available for purchase through both physical stores and online platforms. Additionally, the company provides a mobile application that enables users to easily scan their heads and faces, facilitating the custom fitting process in under two minutes.

The University of Massachusetts Medical School (UMMS), founded in 1962 and located in Worcester, Massachusetts, is dedicated to providing affordable, high-quality medical education with a focus on increasing the number of primary care physicians in underserved areas. Recognized by U.S. News & World Report as a leading institution for primary care education, UMMS aims to enhance health and wellness in diverse communities both locally and globally. The university is committed to innovation in education, research, healthcare delivery, and public service, while its assets are managed by an executive team to support its mission effectively.

The University of Vermont (UVM) is a public research university located in Burlington, Vermont, established in 1791. It is one of the oldest institutions of higher education in the United States and the fifth college founded in New England. UVM offers a diverse array of academic programs through its various schools and colleges, including the School of Business Administration, College of Agriculture and Life Sciences, College of Arts and Sciences, College of Communication, College of Medicine, College of Engineering and Mathematics, Graduate College, College of Nursing and Health Sciences, College of Education and Social Services, and School of Natural Resources. The university's campus spans 451 acres and features notable sites such as the historic University Green, the environmentally certified Dudley H. Davis Center, the Fleming Museum of Art, and the Gutterson/Patrick athletic complex. Additionally, the university is affiliated with Fletcher Allen Health Care, the largest hospital complex in Vermont, which is located adjacent to the campus and collaborates with the College of Medicine.

Quadrant Biosciences Inc. is a life sciences company focused on developing epigenetic diagnostic solutions and biomarker technologies aimed at addressing significant healthcare challenges, particularly in the early identification of neurological disorders such as Autism Spectrum Disorder, concussion, and Parkinson's Disease. Founded in 2015 and based in Syracuse, New York, the company has established collaborative research relationships with various institutions to explore innovative diagnostic and therapeutic solutions. Quadrant Biosciences leverages its expertise in RNA analysis to enhance healthcare delivery and has also contributed to addressing health issues related to the COVID-19 pandemic. The company aims to improve lives through its commitment to advancing molecular diagnostic tools.

If you reside in the Kingston, Rhode Island area and are looking for an undergraduate or graduate program for academic study, why not check out the University of Rhode Island? Programs available to choose from as a major include the interesting Animal and Veterinary Science, Business Administration, Civil and Environmental Engineering, Geology and Geological Oceanography, Human Development and Family Studies, International Engineering, Journalism, and Nursing, among many others. URI has a festive student life which includes both entertainment events and organizations which can help students get a leg up in the career search. Study abroad programs are offered during the summer and school year. There is also a strong Greek life, Student Senate, dining, and athletic programs. Other services include a counseling center and health services. If you qualify for financial aid like the Centennial and University Scholarships, your entire tuition may be covered. There are also grants and loans that can help cover tuition and other educational expenses. When it comes time to search for a job, the career service center can help students with writing resumes, interview preparation, meeting potential employers, and much more.

Aquinnah Pharmaceuticals, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, established in 2014. The company specializes in developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Aquinnah's research focuses on modulating neurodegenerative stress granules, which are thought to play a significant role in the pathology of ALS. Through its innovative approach, Aquinnah aims to address critical unmet medical needs in the treatment of these debilitating conditions.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company specializes in developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its HEALER technology platform, Thetis Pharmaceuticals focuses on the pharmacology of lipids to create new and patented small molecule drugs that promote tissue regeneration and mitigate inflammation. Their research has advanced the development of resolvins, which act as potent agonists of inflammation resolution and tissue repair. These therapies are designed to counteract excessive inflammatory responses while preserving immune function, thereby enabling healthcare professionals to better manage patients' inflammatory conditions.

Envisagenics, Inc. is a biotechnology company founded in 2013 and headquartered in Huntington, New York. It specializes in the development of a predictive analytics platform aimed at accelerating the discovery of RNA therapeutics. The company leverages advanced artificial intelligence and machine learning algorithms to analyze transcriptomic data, helping researchers identify and validate potential drug targets. Envisagenics' flagship technology, SpliceCore, is a cloud-based platform that utilizes RNA splicing analytics to predict drug targets and biomarkers, addressing the complexities of biomedical data. Given that over 30 million people in the U.S. suffer from genetic diseases or cancers related to RNA splicing errors, the company's mission is to streamline the development of innovative therapeutic solutions. By providing an in-silico RNA therapeutics discovery platform, Envisagenics enhances the efficiency of drug development processes, reducing time, cost, and risk associated with bringing new therapies to market through partnerships with biopharmaceutical companies.

Windtree Therapeutics is a biotechnology company focused on the research and development of innovative therapies for acute pulmonary and cardiovascular diseases. The company is advancing several product candidates, including istaroxime, which is undergoing Phase 2b trials for acute decompensated heart failure and Phase 2a trials for early cardiogenic shock. Windtree's portfolio also includes AEROSURF, an aerosolized KL4 surfactant in Phase 2b trials aimed at treating respiratory distress syndrome in premature infants, and a lyophilized KL4 surfactant intended for lung injuries related to COVID-19. Additionally, Rostafuroxin is in Phase 2b trials for genetically associated hypertension. The company utilizes a proprietary technology platform that includes a synthetic surfactant designed to mimic natural pulmonary surfactant, enabling noninvasive delivery methods. Founded in 1992 and headquartered in Warrington, Pennsylvania, Windtree Therapeutics was previously known as Discovery Laboratories until its name change in 2016.

Rutgers University, officially known as Rutgers, The State University of New Jersey, is a prominent institution for higher education, established in 1766 as Queen's College, making it the eighth-oldest college in the United States. As the largest university in New Jersey's state university system, Rutgers offers over 100 undergraduate, 100 master's, and 80 doctoral and professional degree programs across 175 academic departments and 29 degree-granting schools and colleges, with 16 offering graduate programs. The university also has a dedicated School of Law that covers various legal fields. Rutgers manages an endowment fund based in New Brunswick, which serves as a vital source of income to support its mission. This endowment funds student aid, innovative teaching programs, pioneering research, and the development of new technologies.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company focuses on developing and commercializing innovative silk biomaterial technologies. Its key product, the MIMIX microneedle platform, facilitates the transdermal delivery of vaccines and therapeutics. This sustained release patch technology allows for a controlled release of vaccines, mimicking the natural infection process to enhance immune response and effectiveness. Vaxess's patch is engineered for stability, eliminating the need for refrigeration, which enables shipping and application in low-resource settings. In addition to its vaccine delivery systems, Vaxess is also engaged in creating novel therapies aimed at oncology care and infectious diseases, ultimately striving to improve patient outcomes with reduced treatment burdens.

Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company specializes in developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its HEALER technology platform, Thetis Pharmaceuticals focuses on the pharmacology of lipids to create new and patented small molecule drugs that promote tissue regeneration and mitigate inflammation. Their research has advanced the development of resolvins, which act as potent agonists of inflammation resolution and tissue repair. These therapies are designed to counteract excessive inflammatory responses while preserving immune function, thereby enabling healthcare professionals to better manage patients' inflammatory conditions.

Soligenix, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases and public health solutions. The company operates through two primary segments: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics segment, Soligenix is advancing SGX301, a photodynamic therapy for cutaneous T-cell lymphoma that has completed Phase 3 clinical trials, and SGX942, aimed at treating oral mucositis in head and neck cancer, currently in Phase 3 trials. Additionally, it is developing an oral formulation of beclomethasone dipropionate for severe gastrointestinal disorders in early clinical trials. The Public Health Solutions segment focuses on biodefense, including the development of RiVax, a vaccine candidate against ricin toxin, which has completed early clinical trials, and SGX943, a therapeutic for antibiotic-resistant infections that is in pre-clinical development. The company also works on technologies like ThermoVax, aimed at stabilizing vaccines. Soligenix was founded in 1987 and is based in Princeton, New Jersey.

Novo Biosciences develops cardiac drugs designed to reverse the life-threatening damage caused by heart attacks. Its drugs spur the body to heal itself by triggering powerful mechanisms of self-repair and regrowth that lie dormant in genes, enabling patients to regenerate damaged organs and tissues and live a healthier life. The company was founded in 2013 and is headquartered in Bar Harbor, Maine.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Aldatu Biosciences Inc. specializes in diagnostics for detecting drug resistance in antiretroviral treatments for HIV. The company utilizes its proprietary PANDAA technology, developed at Harvard University, to provide a robust solution for HIV genotyping. This platform enables healthcare providers to match patients with appropriate drugs, ultimately enhancing patient outcomes and reducing the overall costs associated with HIV care. Founded in 2014 and based in Cambridge, Massachusetts, Aldatu Biosciences is committed to advancing global health through innovative diagnostic solutions that address both infectious diseases and emerging health challenges. As a Public Benefit Corporation, the company focuses on improving patient care and healthcare cost efficiency worldwide.

EpiVax, Inc. is a biotechnology company specializing in the development of computational immunology tools to enhance immunotherapeutics. Based in Providence, Rhode Island, EpiVax provides a range of services including interactive protein screening, immunogenicity predictions for antibodies, and risk assessments of host cell protein contaminants. The company's offerings include high-throughput antibody immunogenicity reports, deimmunization solutions to mitigate immunogenic risks in protein therapeutics, and lab-based services such as HLA binding assays and T cell assays. Additionally, EpiVax is involved in the development of Tregitopes, which are sequences within monoclonal antibodies that activate regulatory T cells, as well as various epitope-based vaccines targeting diseases like smallpox and influenza. Founded in 1998, EpiVax leverages a blend of collaborative and internal programs to advance the field of immunology and provide safer immunotherapeutic options.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Soterix Medical develops devices and accessories based on neuromodulation and brain stimulation technologies. The company was founded by Abhishek Datta and is based in New York, the United States.

Sober Grid, Inc. operates a digital health platform that serves as a sober social network, facilitating connections among individuals recovering from substance use disorders. Launched in 2015 and headquartered in Boston, Massachusetts, the application is available on both Apple and Android devices and has been utilized over 20 million times across more than 170 countries. Developed in collaboration with researchers from Harvard Medical School and the University of Pennsylvania, Sober Grid employs a community-based approach to chronic disease management, incorporating evidence-based recovery tools and predictive analytics to assess relapse risk. The app features a GPS locator for users to find nearby sober individuals, along with direct messaging, a newsfeed, and access to certified coaching available 24/7. By combining technology with human connection, Sober Grid aims to improve health outcomes through real-time support and engagement, catering to a growing population of individuals in recovery.

Brown University Endowment is the investment arm of Brown University, located in Providence, Rhode Island, and founded in 1764. The endowment consists of various individual funds, including both donor-restricted and corporate-designated funds, aimed at maintaining the university's purchasing power and providing a stable financial resource for its operations. It invests across a diverse range of asset classes, including public equity, fixed income, real estate, commodities, and alternative markets. The endowment employs strategies such as long/short hedging to optimize its investment performance. Managed by the Brown University Investment Office under the oversight of the board of trustees, the endowment plays a crucial role in supporting the university’s commitment to exceptional education and research, serving approximately 8,000 students across its undergraduate, graduate, and medical programs.

Roswell Park Cancer Institute (RPCI), America's first cancer center founded in 1898 by Dr. Roswell Park. His revolutionary model of a “multidisciplinary approach” to cancer — with scientists and clinicians working in concert and in consult — has become the standard by which all modern-day comprehensive cancer centers are measured. RPCI is among the first and only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center" and to serve as a member of the prestigious National Comprehensive Cancer Network. Many RPCI faculty serve on the NCCN panels that create the Clinical Practice Guidelines in Oncology™ — the internationally recognized standards for clinical policy in oncology, and the most comprehensive, most frequently updated clinical practice guidelines available in any area of medicine.

TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and based in Arlington, Massachusetts, the company utilizes its proprietary TetraExpress system to produce recombinant human ion channel proteins and other complex biologics. TetraGenetics specializes in the production of eukaryotic membrane and secretory proteins, which are often difficult to express using conventional systems. Among its products is IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. The company is also engaged in a strategic research and development collaboration with Imbrium Therapeutics L.P., aiming to address autoimmune diseases and provide solutions for ion channel-related conditions. TetraGenetics' technology enables rapid production of properly folded, functional transmembrane proteins, positioning the company as a valuable player in the development of novel therapeutics and vaccines for both human and animal health.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

Envisagenics, Inc. is a biotechnology company founded in 2013 and headquartered in Huntington, New York. It specializes in the development of a predictive analytics platform aimed at accelerating the discovery of RNA therapeutics. The company leverages advanced artificial intelligence and machine learning algorithms to analyze transcriptomic data, helping researchers identify and validate potential drug targets. Envisagenics' flagship technology, SpliceCore, is a cloud-based platform that utilizes RNA splicing analytics to predict drug targets and biomarkers, addressing the complexities of biomedical data. Given that over 30 million people in the U.S. suffer from genetic diseases or cancers related to RNA splicing errors, the company's mission is to streamline the development of innovative therapeutic solutions. By providing an in-silico RNA therapeutics discovery platform, Envisagenics enhances the efficiency of drug development processes, reducing time, cost, and risk associated with bringing new therapies to market through partnerships with biopharmaceutical companies.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

The Vermont Genetics Network (VGN) is funded by a five-year, $16.5 million award from the National Center for Research Resources (NCRR), and is part of a National Institutes of Health (NIH) initiative called IDeA Networks of Biomedical Research Excellence (INBRE). Under the direction of Dr. Judith Van Houten, the VGN, which links scientists at Castleton State College, Johnson State College, Middlebury College, Norwich University and St. Michael's College to resources at UVM, is designed to provide funding for research, equipment and technology necessary to enhance competitiveness for national funding for genetics research. Other aims of the project include increasing the number of undergraduates who go on to biomedical careers from the baccalaureate colleges, to provide and support bioinformatics capability in the state, and to increase the diversity of biomedical scientists.

Aldatu Biosciences Inc. specializes in diagnostics for detecting drug resistance in antiretroviral treatments for HIV. The company utilizes its proprietary PANDAA technology, developed at Harvard University, to provide a robust solution for HIV genotyping. This platform enables healthcare providers to match patients with appropriate drugs, ultimately enhancing patient outcomes and reducing the overall costs associated with HIV care. Founded in 2014 and based in Cambridge, Massachusetts, Aldatu Biosciences is committed to advancing global health through innovative diagnostic solutions that address both infectious diseases and emerging health challenges. As a Public Benefit Corporation, the company focuses on improving patient care and healthcare cost efficiency worldwide.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company focuses on developing and commercializing innovative silk biomaterial technologies. Its key product, the MIMIX microneedle platform, facilitates the transdermal delivery of vaccines and therapeutics. This sustained release patch technology allows for a controlled release of vaccines, mimicking the natural infection process to enhance immune response and effectiveness. Vaxess's patch is engineered for stability, eliminating the need for refrigeration, which enables shipping and application in low-resource settings. In addition to its vaccine delivery systems, Vaxess is also engaged in creating novel therapies aimed at oncology care and infectious diseases, ultimately striving to improve patient outcomes with reduced treatment burdens.

Daktari Diagnostics, Inc. is a healthcare solutions company based in Cambridge, Massachusetts, founded in 2008. The company specializes in developing portable point-of-care diagnostic platforms aimed at improving disease management worldwide, particularly in resource-poor settings. Its key offerings include the Daktari Virology platform for detecting Hepatitis C and HIV, the Daktari InSight data management service that facilitates connectivity between diagnostic systems and healthcare providers, and the Daktari Sickle Cell solution, which enables the identification of infants with sickle cell disease from a single drop of blood. Daktari's products are designed to provide real-time diagnostic information while ensuring that critical data flows efficiently throughout the healthcare system, ultimately supporting better clinical outcomes and global disease elimination efforts.

First Light Diagnostics Inc. specializes in the development of automated medical diagnostic products aimed at detecting microbes responsible for healthcare-associated infections. The company is known for its benchtop MultiPath analyzer, which identifies both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses, making it suitable for hospital clinical microbiology laboratories. Its products address multiple applications, including the screening of blood, surgical, skin, and gastrointestinal infections. By offering rapid and cost-effective testing solutions, First Light Diagnostics meets the increasing demand for accurate diagnostics, which is essential for reducing hospital infection rates. The company's proprietary MultiPath detection technology combines the efficiency of advanced laboratory tests with affordability and ease of use. Founded in 2006 and based in Chelmsford, Massachusetts, First Light Diagnostics was previously known as First Light Biosciences until its name change in January 2019.

Boston Medical Center is a private, not-for-profit, academic medical center that provides its patients with trauma and emergency services. It is dedicated to providing accessible health care services to everyone. It also offers many outreach programs and services such as health screenings, smoking cessation, prevention food pantry, bWell center, and interpreter services. Boston Medical Center is based in Boston, Massachusetts.

OncoSec Medical is a biotechnology company that specializes in developing cytokine-based intratumoral immunotherapies aimed at enhancing the body's immune response against cancer. The company's lead product, ImmunoPulse IL-12, employs an electroporation device to deliver a DNA-encoded interleukin-12, which helps to counteract the immunosuppressive environment within tumors. OncoSec is currently conducting Phase IIb clinical trials of ImmunoPulse IL-12 in combination with KEYTRUDA for advanced melanoma and is also exploring its efficacy in treating advanced or metastatic triple-negative breast cancer. The company has completed Phase II trials for various indications, including monotherapy for metastatic melanoma. Additionally, OncoSec is investigating new therapeutic candidates to address deep visceral lesions in organs such as the liver and lungs. Collaborations include partnerships with Merck & Co. and research institutions like Duke University and Roswell Park Comprehensive Cancer Center. Founded in 2008 and based in Pennington, New Jersey, OncoSec was previously known as NetVentory Solutions Inc. until its name change in 2011.

Windtree Therapeutics is a biotechnology company focused on the research and development of innovative therapies for acute pulmonary and cardiovascular diseases. The company is advancing several product candidates, including istaroxime, which is undergoing Phase 2b trials for acute decompensated heart failure and Phase 2a trials for early cardiogenic shock. Windtree's portfolio also includes AEROSURF, an aerosolized KL4 surfactant in Phase 2b trials aimed at treating respiratory distress syndrome in premature infants, and a lyophilized KL4 surfactant intended for lung injuries related to COVID-19. Additionally, Rostafuroxin is in Phase 2b trials for genetically associated hypertension. The company utilizes a proprietary technology platform that includes a synthetic surfactant designed to mimic natural pulmonary surfactant, enabling noninvasive delivery methods. Founded in 1992 and headquartered in Warrington, Pennsylvania, Windtree Therapeutics was previously known as Discovery Laboratories until its name change in 2016.

The Miriam Hospital is a private, not-for-profit hospital at 164 Summit Avenue in Providence, in the U.S. state of Rhode Island. It is a major teaching affiliate of the Warren Alpert Medical School of Brown University.

Artaic, LLC is a Boston-based company that specializes in designing and fabricating custom tile work for both commercial and residential markets. Founded in 2007 by Ted Acworth, Artaic focuses on innovative mosaics that enhance the architecture and interior design sectors. Utilizing advanced technology, including computer-aided design software and a robotic mosaic assembly system, the company offers a wide range of applications, such as bathroom backsplashes, flooring, and public art installations. Artaic's approach allows for complete control over the color, material, and layout of its mosaics, enabling clients to achieve customized designs while minimizing costs. Additionally, the company provides installation services, further streamlining the process for its clientele.

Roswell Park Cancer Institute (RPCI), America's first cancer center founded in 1898 by Dr. Roswell Park. His revolutionary model of a “multidisciplinary approach” to cancer — with scientists and clinicians working in concert and in consult — has become the standard by which all modern-day comprehensive cancer centers are measured. RPCI is among the first and only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center" and to serve as a member of the prestigious National Comprehensive Cancer Network. Many RPCI faculty serve on the NCCN panels that create the Clinical Practice Guidelines in Oncology™ — the internationally recognized standards for clinical policy in oncology, and the most comprehensive, most frequently updated clinical practice guidelines available in any area of medicine.

Windtree Therapeutics is a biotechnology company focused on the research and development of innovative therapies for acute pulmonary and cardiovascular diseases. The company is advancing several product candidates, including istaroxime, which is undergoing Phase 2b trials for acute decompensated heart failure and Phase 2a trials for early cardiogenic shock. Windtree's portfolio also includes AEROSURF, an aerosolized KL4 surfactant in Phase 2b trials aimed at treating respiratory distress syndrome in premature infants, and a lyophilized KL4 surfactant intended for lung injuries related to COVID-19. Additionally, Rostafuroxin is in Phase 2b trials for genetically associated hypertension. The company utilizes a proprietary technology platform that includes a synthetic surfactant designed to mimic natural pulmonary surfactant, enabling noninvasive delivery methods. Founded in 1992 and headquartered in Warrington, Pennsylvania, Windtree Therapeutics was previously known as Discovery Laboratories until its name change in 2016.

Daktari Diagnostics, Inc. is a healthcare solutions company based in Cambridge, Massachusetts, founded in 2008. The company specializes in developing portable point-of-care diagnostic platforms aimed at improving disease management worldwide, particularly in resource-poor settings. Its key offerings include the Daktari Virology platform for detecting Hepatitis C and HIV, the Daktari InSight data management service that facilitates connectivity between diagnostic systems and healthcare providers, and the Daktari Sickle Cell solution, which enables the identification of infants with sickle cell disease from a single drop of blood. Daktari's products are designed to provide real-time diagnostic information while ensuring that critical data flows efficiently throughout the healthcare system, ultimately supporting better clinical outcomes and global disease elimination efforts.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Kitware develops and supports open-source software in the fields of computer vision, medical imaging, visualization, 3D data publishing, and technical software development. Its solutions include Insight Segmentation and Registration Toolkit, an open-source software system to support the VisibleHuman project; CMake, a cross-platform open-source make system to control the software compilation process using platform and compiler independent configuration files; Visualization ToolKit, an open source software system for 3D computer graphics, image processing, and visualization for researchers and developers around the world; KiwiViewer, an interactive application for the exploration of geometric datasets on multi-touch mobile devices; and MIDAS, a multi-media server for storing scientific data and related metadata reports. The company also provides ActiViz, which provides an interface to the Visualization Toolkit, an object-oriented interface that encompasses various algorithms to transform data into interactive 3D environments; VolView, an interactive system for volume visualization that allows researchers to explore and analyze 3D medical or scientific data on Windows and Unix platforms; CDashPro, a dashboard hosting service that aggregates, analyzes, and displays the results of software testing processes; and ParaViewPro, a professional support subscription for the ParaView scientific visualization application. Kitware was founded in 1998 and is based in Clifton Park, New York.

Noom, Inc. is a digital health company that specializes in mobile health coaching solutions aimed at helping individuals manage and prevent chronic conditions such as obesity, diabetes, and hypertension. Founded in 2008 and headquartered in New York City, Noom offers a psychology-based platform that integrates evidence-based curricula with trained cognitive behavior coaches, mobile tracking, and scalable coaching tools. The platform empowers users to achieve their personal health and wellness goals, including weight management and stress reduction. Noom has received multiple grants from the National Institutes of Health and is recognized as a certified diabetes prevention program by the Centers for Disease Control. In addition to serving individual users, Noom also partners with businesses to promote health and wellness initiatives. The company has additional offices in Seoul, South Korea, and Tokyo, Japan.

Roswell Park Cancer Institute (RPCI), America's first cancer center founded in 1898 by Dr. Roswell Park. His revolutionary model of a “multidisciplinary approach” to cancer — with scientists and clinicians working in concert and in consult — has become the standard by which all modern-day comprehensive cancer centers are measured. RPCI is among the first and only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center" and to serve as a member of the prestigious National Comprehensive Cancer Network. Many RPCI faculty serve on the NCCN panels that create the Clinical Practice Guidelines in Oncology™ — the internationally recognized standards for clinical policy in oncology, and the most comprehensive, most frequently updated clinical practice guidelines available in any area of medicine.

Artaic, LLC is a Boston-based company that specializes in designing and fabricating custom tile work for both commercial and residential markets. Founded in 2007 by Ted Acworth, Artaic focuses on innovative mosaics that enhance the architecture and interior design sectors. Utilizing advanced technology, including computer-aided design software and a robotic mosaic assembly system, the company offers a wide range of applications, such as bathroom backsplashes, flooring, and public art installations. Artaic's approach allows for complete control over the color, material, and layout of its mosaics, enabling clients to achieve customized designs while minimizing costs. Additionally, the company provides installation services, further streamlining the process for its clientele.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.